Pharmaceutical supply chains face mounting pressure to maintain precise product traceability at every stage of the distribution process.
Aggregation, the process of linking serialised items to their parent containers, has emerged as a critical discipline for manufacturers and logistics operators alike.
When cases are broken down or mixed pallets are built, maintaining the relationship between individual serialised products becomes significantly more complex without proper aggregation in place.
Without aggregation, operators are forced to re-scan individual items at multiple points in the supply chain, adding time, cost, and the potential for human error at every step.
The pharmaceutical sector operates under strict regulatory requirements around serialisation, meaning that any gap in product traceability can carry serious compliance consequences for businesses.
Aggregation addresses this challenge directly by recording the hierarchical relationship between individual packs, cases, and pallets as products move through the supply chain.
When a pallet is received or a case is broken open, an aggregated record allows downstream handlers to know exactly what serialised units are present without conducting a full re-scan.
This capability becomes particularly valuable in complex distribution environments where mixed pallets are commonplace and the manual effort of item-level scanning would be operationally prohibitive.
Industry specialists at Körber have highlighted that failing to implement aggregation correctly results in costly operational delays that compound across the entire supply network.
The business case for aggregation extends beyond compliance, offering pharmaceutical companies a tangible opportunity to reduce operational overhead and improve the accuracy of their inventory data.
Manufacturers investing in robust aggregation processes are better positioned to respond quickly to product recalls, reducing the time needed to identify and isolate affected serialised units across distribution networks.
As regulatory scrutiny around pharmaceutical traceability continues to increase globally, aggregation is transitioning from a best practice recommendation to an operational baseline expectation across the industry.